Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy | Zendy

Susumu Ogawa | Zendy; Hiroyuki Kobori | Zendy; Naro Ohashi | Zendy; Maki Urushihara | Zendy; Akira Nishiyama | Zendy; Takefumi Mori | Zendy; Tsuneo Ishizuka | Zendy; Kazuhiro Nako | Zendy; Sadayoshi Ito | Zendy

Open Access

Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy

Author(s) -

Susumu Ogawa,

Hiroyuki Kobori,

Naro Ohashi,

Maki Urushihara,

Akira Nishiyama,

Takefumi Mori,

Tsuneo Ishizuka,

Kazuhiro Nako,

Sadayoshi Ito

Publication year - 2009

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s2733

Subject(s) - medicine , endocrinology , diabetic nephropathy , urinary system , creatinine , oxidative stress , angiotensin ii , excretion , blood pressure , hypertensive nephropathy , urology , diabetes mellitus

To demonstrate that the administration of an angiotensin (Ang) II type 1 receptor (AT1R) blocker (ARB) inhibits the vicious cycle of high glucose (HG)-reactive oxygen species (ROS)-angiotensinogen (AGT)-Ang II-AT1R-ROS by suppressing ROSs and inflammation, thus ameliorating diabetic nephropathy (DN).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research